Mealey's (February 8, 2019, 9:04 AM EST) -- WASHINGTON, D.C. — A Massachusetts federal judge correctly concluded that a patented method of diagnosing certain neurological disorders, including myasthenia gravis (MG), through the detection of muscle-specific tyrosine kinase (MuSK) protein antibodies is directed to a natural law and lacks an inventive concept, a divided Federal Circuit U.S. Court of Appeals ruled Feb. 6 (Athena Diagnostics Inc. v. Mayo Collaborative Services LLC, No. 17-2508, Fed. Cir., 2019 U.S. App. LEXIS 3645)....